Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. (LLY:Quote) said Friday that the U.S. Food and Drug Administration has approved a supplemental new drug application, or sNDA, for Tradjenta tablets for use as add-on therapy to insulin. Tradjenta (linagliptin) is a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The drug can be used as monotherapy or in combination with other commonly prescribed medications for type 2 diabetes, such as metformin, sulfonylurea, pioglitazone or insulin. Tradjenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine).
